Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies

Fig. 4

Proportion of patients achieving MCID for FACIT-Fatigue in A MTX-naïve patients, B MTX-IR patients, and C bDMARD-IR patients. Comparison with placebo or methotrexate: ***P < 0.001, **P < 0.01, *P < 0.05. Comparison with adalimumab: †P < 0.05. All P values are exploratory (not adjusted for multiplicity) and were from logistic regression with treatment groups and stratification factors in the model. A nonresponder imputation was used for patients with missing data. MCID was defined as a ≥ 4-point increase from baseline. In the MTX-IR study, patients on PBO were rerandomized to FIL 200 or 100 mg at week 24. The bDMARD-IR study ended at week 24. ADA, adalimumab; bDMARD, biologic DMARD; csDMARD, conventional synthetic DMARD; DMARD, disease-modifying antirheumatic drug; FACIT, Functional Assessment of Chronic Illness Therapy; FIL, filgotinib; MCID, minimal clinically important difference; MTX, methotrexate; PBO, placebo

Back to article page